Annexon (ANNX) vs Obsidian Therapeutics (OBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Obsidian Therapeutics is the larger company by market cap ($770.3 million vs $757.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | OBX |
|---|---|---|
| Share price | $4.00 | $12.47 |
| Market cap | $757.37M | $770.31M |
| 1-day change | -0.37% | -5.53% |
| YTD return | -20.12% | — |
| 1-year return | +30.62% | — |
| 5-year return | -81.77% | — |
| EPS (TTM) | $-1.13 | $-1.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $49.97 |
| 52-week low | $2.54 | $12.16 |
| Distance from 52-week high | -44.36% | -75.05% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +286.23% | +212.75% |
| Average volume | 3.11M | 364.47K |
| Shares outstanding | 189.58M | 61.77M |
| Employees | 92 | 87 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 92 employees
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ANNX vs OBX FAQ
Which is bigger, Annexon or Obsidian Therapeutics?
Obsidian Therapeutics (OBX) is larger, with a market capitalization of $770.31M compared with $757.37M for Annexon (ANNX).
Are Annexon and Obsidian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.